NLS Pharma

11 articles with NLS Pharma

• NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

  3/29/2021

   NLS Pharmaceutics Ltd.announces that it has been awarded Canadian Patent No. 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

• NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)

  3/12/2021

  Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S.

• NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public Offering

  2/2/2021

  NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the closing of its initial public offering of 4,819,277 units

• NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy

  1/21/2021

  NLS Pharmaceutics Ltd., a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including narcolepsy, idiopathic hypersomnia and Kleine-Levin Syndrome and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, announced that the European Patent Office issued a Notice of Intention to Grant NLS's patent application covering a novel formulation of mazindol for treatment of ADHD and sleep related disorders.

• NLS Pharma Touts Positive Phase II ADHD Data

  5/31/2017

• NLS Pharma Announces New Information In Support Of The Mechanism Of Action Of Its Lead Compound NLS-1 Mazindol CR

  5/30/2017

• NLS Pharma Announces Phase ll Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And Secondary Endpoints

  5/16/2017

• NLS Pharma Announces Completion Of Phase II Study For NLS-1, Its Lead ADHD Compound; New Investors, New Patents

  4/18/2017

• NLS Pharma Announces Start Of Its Phase 2 Trial For Mazindol In Adult ADHD Patients

  8/29/2016

• NLS Pharma Release: FDA Accepts IND For Phase II Study Of Mazindol In Adults With ADHD

  6/16/2016

• NLS Pharma Announces Submission Of Investigational New Drug (IND) Application To FDA For Its Controlled-Release Mazindol For The Treatment Of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

  5/12/2016